98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12088833 | PMC |
http://dx.doi.org/10.1111/cea.70019 | DOI Listing |
Clin Exp Allergy
May 2025
Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
PLoS One
January 2014
Centre of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
The feasibility of cancer immunotherapy mediated by T lymphocytes is now a clinical reality. Indeed, many tumour associated antigens have been identified for cytotoxic CD8 T cells, which are believed to be key mediators of tumour rejection. However, for aggressive malignancies in specialised anatomic sites such as the brain, a limiting factor is suboptimal tumour infiltration by CD8 T cells.
View Article and Find Full Text PDFPLoS Pathog
September 2011
UPMC Univ Paris 6, UMR_S 938, Centre de Recherche Hôpital Saint-Antoine, Paris, France.
Several hurdles must be overcome in order to achieve efficient and safe immunotherapy against conformational neurodegenerative diseases. In prion diseases, the main difficulty is that the prion protein is tolerated as a self protein, which prevents powerful immune responses. Passive antibody therapy is effective only during early, asymptomatic disease, well before diagnosis is made.
View Article and Find Full Text PDFMediators Inflamm
October 2003
Division of Infectious Diseases, University of British Columbia, Vancouver, Canada.
Background: T helper cell polarisation is important under chronic immune stimulatory conditions and drives the type of the evolving immune response. Mice treated with superantigens in vivo display strong effects on Th subset differentiation. The aim of the study was to detect the intrinsic capacity of T cells to polarise under various ex vivo conditions.
View Article and Find Full Text PDF